Melphalan / Melfalán 50mg
Product Overview
| Generic Name | Melphalan / Melfalán 50mg |
| Brand Name(s) | Alkeran® |
| Category | Antineoplastic / Cancer |
| Form | single use vial, inj Lyophilised powder |
| Strength | 50 mg |
| Therapeutic Class | Alkylating antineoplastic agent; nitrogen mustard analogue; |
| ATC Code | L01AA03 |
Manufacturing & Regulatory
| Manufacturer | Natco, Celon, Cipla |
| GMP Compliance | WHO-GMP |
| COFEPRIS | N/A |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 vials |
| Shelf Life | 24 Months |
| Storage | Refrigerated 2°C–8°C; do not freeze; protect from light |
| Incoterms | EXW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Melphalan 50 mg injectable lyophilised powder is a hospital-administered cytotoxic alkylating agent used in specialist oncology and haematology settings. Conventional IV melphalan is used for palliative treatment of multiple myeloma when oral therapy is not appropriate and for palliation of non-resectable ovarian carcinoma in certain references; high-dose melphalan regimens are also used as conditioning treatment before haematopoietic progenitor/stem-cell transplantation in multiple myeloma. Use requires specialist supervision due to severe myelosuppression, infection and bleeding ris